Navigation Links
Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
Date:5/31/2011

MOUNTAIN VIEW, Calif., May 31, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the European Congress on Obesity (ECO) in Istanbul, Turkey.  ECO is the official obesity congress of The European Association for the Study of Obesity (EASO). ECO is regularly attended by more than 2500 participants from over 75 countries and is considered to be the most important annual scientific event on obesity in Europe.  

Highlights from the ECO presentations were as follows:

A poster presentation authored by W. Timothy Garvey, MD from the University of Alabama at Birmingham reported reductions in progression to type 2 diabetes and improvement in glycemic status in CONQUER patients that were ADA-defined as prediabetics at baseline.  Of the 2,487 patients in the CONQUER study, 1,119 were determined to have prediabetes.  In the prediabetics treated with QNEXA, hemoglobin A1c, fasting glucose and fasting insulin were significantly improved at week 56 (ITT-LOCF p<0.005 vs. placebo).  In the prediabetic population significantly more QNEXA treated patients achieved normal blood sugar levels (p=0.0016) and significantly more patients on placebo were progressed to type 2 diabetics as compared to the QNEXA treated patients (p=0.0253).  

"For this set of patients, QNEXA treatment led to benefits above and beyond losing weight.  The results highlighted by Dr Garvey showed that weight loss after 56 weeks of treatment led to an improvement in glycemic status and reduction of progression to type 2 diabetes.  This clinically important finding further strengthens the QNEXA benefit profile," added Barbara Troupin, MD, senior director of medical affairs for VIVUS.  

The CONQUER study included 2,487 patients that had two or more comorbidities studied over 56 weeks. 
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Hope Paige Designs Medical ID Bracelets Now Available in 1,100 Additional Locations
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
4. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Rosetta Genomics Announces Issuance of Additional U.S. Patent
7. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
8. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
9. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
10. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
11. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  GenSpera, Inc. (OTCQB: ... the treatment of cancer, announces that Kareg Corporation,s ... has issued the following research report on  the ... , Director of Research, Kareg Corporation, Initiating Coverage ... Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf ...
(Date:7/14/2014)... -- Medac Pharma, Inc., a privately held pharmaceutical company ... improving the effectiveness of existing medicines, announced that ... approved Rasuvo™, a subcutaneous injectable methotrexate (MTX) therapy ... polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo ... from 7.5 mg to 30 mg in 2.5 ...
(Date:7/14/2014)... Ill., July 14, 2014  Abbott (NYSE: ABT) announced today ... pharmaceuticals business to Mylan for equity ownership of a ... and Abbott,s developed markets pharmaceuticals ... represents a value of approximately $5.3 billion based on ... portion of this business generated approximately $2 billion in ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... Va., Aug. 26 Radiation in any form brings risk. ... designed with safeguards in mind to minimize the risk and ... if a patient presents with a breast lump that can ... professionals must employ the most appropriate diagnostic tools that identify ...
... Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company -- JERUSALEM, August 26, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
Cached Medicine Technology:Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 2Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 2Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 4Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 5Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 6
(Date:7/14/2014)... The report “Biofertilizers Market ... Type (Cereals & Grains, Pulses & Oilseeds, ... Azospirillium, Cyanobacteria, Phosphate solubilizing bacteria), & by ... 2019” defines and segments the biofertilizers market ... values for the market. It also identifies ...
(Date:7/14/2014)... E.J. Mundell ... News) -- When an 11-year-old boy in San Diego ... the nickel in his family,s iPad. They also ... iPad,s metal surfaces with a form-fitting case. The ... personal effects as potential sources of nickel exposure" and ...
(Date:7/14/2014)... specialists look back on 40 years of the Glasgow Coma ... research and clinical practice, in a new Personal View published ... The Personal View is published on the 40th anniversary of ... Since this seminal publication, the Glasgow Coma Scale has ... conscious level, the clinical hallmark of acute brain injury. The ...
(Date:7/14/2014)... to ignore irrelevant stimuli underlies the impaired working memory ... reports a new study in the current issue of ... good at focusing on the information that we are ... thoughts that aren,t relevant. However, memory impairment in schizophrenia ... this filtering process, which Dr. Teal Eich at Columbia ...
(Date:7/14/2014)... N.J. (PRWEB) July 14, 2014 Documented ... Laurel, has announced the publication of its first military memoir ... crash on Black Thursday in October 1943 and 19 months ... to return home and build the American dream. , ... and the American dream (Amazon) is a true ...
Breaking Medicine News(10 mins):Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 2Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 3Health News:Biofertilizers Market worth $1,649.7 Million by 2019 - A Report by MarketsandMarkets 4Health News:iPads Can Trigger Nickel Allergies in Kids 2Health News:'Noisy' memory in schizophrenia 2Health News:Mount Laurel-based Documented Legacy to Release Military Memoir of World War II Air Force Vet Who Survived Black Thursday Crash 2
... HealthDay Reporter , FRIDAY, March 16 (HealthDay ... for kids who have a genetic predisposition to aggressive ... new research suggests. "There,s an intricate interplay between ... assistant professor of criminology at the University of Texas ...
... Musicians and their instruments often make beautiful music together, but ... of musical instruments may put their owners at risk for ... Contact dermatitis is a rash caused by an irritant or ... components of musical instruments -- such as metals, exotic woods ...
... Obesity appears to significantly increase the risk of death ... mortality even among those prescribed 18 or fewer pills ... as a marker of increased vulnerability," said Robert Langer, ... and Prevention | Nutrition, Physical Activity and Metabolism 2012 ...
... companies in overcoming common issues associated with crystal formation ... The software, which has been developed at the University ... Centre (CCDC) is called Visual HABIT. It offers a ... companies to adopt a more ,bottom up, approach to ...
... , FRIDAY, March 16 (HealthDay News) -- People with ... risk for health problems that affect the heart, an ... of psoriasis. Chronic inflammation is also a characteristic of ... said Dr. Joel Gelfand, an assistant professor of dermatology ...
... facilitate efficient production of chemicals, materials and fuels from ... Excellence (CoE) in White Biotechnology Green Chemistry Research ... or cell factories, for producing new useful compounds from ... for example, for manufacturing bioplastics or in medical applications. ...
Cached Medicine News:Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 2Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 3Health News:Tooting Your Horn Can Raise Risk for Skin Condition 2Health News:Obesity raises death risk tied to sleeping pills 2Health News:Obesity raises death risk tied to sleeping pills 3Health News:New technology to aid crystallization prediction 2Health News:Psoriasis Patients May Face Higher Heart Risk 2Health News:Novel plastics and textiles from waste with the use of microbes 2
This double-up gel dryer system, 100-120 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... GelAir™ drying system utilizes a hot air drying ... dried on a clear cellophane support for easy ... a smooth, flat assembly surface for the drying ... frames at once. This 115 V, 60 Hz ...
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
Medicine Products: